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Shiga Toxin-Producing Escherichia coli: a Single-Center, 11-Year
Pediatric Experience
Emily I. Schindler,a,b Patricia Sellenriek,c Gregory A. Storch,d Phillip I. Tarr,e,f Carey-Ann D. Burnhamb
Barnes Jewish Hospital, St. Louis, Missouri, USAa; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USAb; St. Louis
Children’s Hospital, St. Louis, Missouri, USAc; Division of Infectious Diseases, Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St.
Louis, Missouri, USAd; Division of Gastroenterology, Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USAe;
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USAf
The aim of this study was to identify the best practices for the detection of Shiga toxin-producing Escherichia coli (STEC) in chil-
dren with diarrheal illness treated at a tertiary care center, i.e., sorbitol-MacConkey (SMAC) agar culture, enzyme immunoassay
(EIA) for Shiga toxin, or the simultaneous use of both methods. STEC was detected in 100 of 14,997 stool specimens submitted
for enteric culture (0.7%), with 65 cases of E. coliO157. Among E. coliO157 isolates, 57 (88%) were identified by both SMAC
agar culture and EIA, 6 (9%) by SMAC agar culture alone, and 2 (3%) by EIA alone. Of the 62 individuals with diarrheal hemo-
lytic uremic syndrome (HUS) seen at our institution during the study period, 16 (26%) had STEC isolated from cultures at our
institution and 15 (24%) had STEC isolated at other institutions. No STEC was recovered in 31 cases (50%). Of the HUS cases in
which STEC was isolated, 28 (90%) were attributable to E. coliO157 and 3 (10%) were attributable to non-O157 STEC. Consis-
tent with previous studies, we have determined that a subset of E. coliO157 infections will not be detected if an agar-based
method is excluded from the enteric culture workup; this has both clinical and public health implications. The best practice
would be concomitant use of an agar-based method and a Shiga toxin EIA, but a Shiga toxin EIA should not be considered to be
an adequate stand-alone test for detection of E. coliO157 in clinical samples.
Shiga toxin-producing Escherichia coli (STEC) causes a spec-trum of disease, with manifestations ranging from mild self-
limited diarrhea to the life-threatening hemolytic uremic syn-
drome (HUS) (1–7). The incidence and severity of STEC
infections are highest in children, with disproportionate numbers
of HUS cases being reported for this group (7–10).E. coliO157:H7
is the serotype most often implicated in HUS worldwide (1, 9,
11–15).
In 2009, the US Centers for Disease Control and Prevention
(CDC) published guidelines indicating that laboratories should
simultaneously perform a selective and differential agar-based test
to detect E. coli O157 and a test to detect Shiga toxins or Shiga
toxin genes for all stool samples submitted for bacterial culture
(16). These complementary methods are recommended because
of the increasing recognition that non-O157:H7 STEC strains
cause disease and the lack of evidence that STEC enzyme immu-
noassays (EIAs) are as good as or better than sorbitol-MacConkey
(SMAC) agar screening for the detection of E. coli O157, which
remains the most clinically actionable STEC serotype. Further-
more, some studies suggest that a toxin EIA is inferior to SMAC
agar screening for detecting E. coli O157:H7 (14, 17–24).
Infections with STEC are rare (FoodNet data suggest that ap-
proximately 4,000 cases of E. coli O157:H7 infections per year
occur in the United States) (25) but, for the individuals infected,
there are considerable benefits to making a timely diagnosis. Spe-
cifically, the earlier a microbiological diagnosis is attained, the
better the clinical outcome is (26). Moreover, by identifying STEC
as the probable cause of illness that is often quite severe, clinical
care can be focused. However, concern remains that uniform
screening of all stool samples for these pathogens has little public
health or clinical value. Advocates for limiting STEC testing to
“request-only” status encourage laboratories to consider local dis-
ease prevalence, seasonal incidence, and costs before implement-
ing the CDC guidance (24, 27, 28). The counterpoint to this argu-
ment is that broad STEC screening prevents severe clinical
outcomes through early detection and optimization of care. Best
practices dictate that intravenous hydration and conservative
management of severe diarrhea be instituted as expeditiously as
possible, and laboratory detection of a STEC strain often prompts
such interventions (2, 26, 29).
Considering the costs of parallel testing and the paucity of data
on which to judge the merits of the CDC guidelines, many labo-
ratories do not perform STEC testing unless it is specifically re-
quested, and nearly 10% of laboratories have abandoned agar-
based testing in favor of exclusively performing EIAs for Shiga
toxin detection (30). The St. Louis Children’s Hospital (SLCH)
microbiology laboratory has followed the practice of performing
simultaneous SMAC agar cultures and STEC EIAs for all stool
specimens since 2001; this practice was recommended by the CDC
in 2009. Our objectives in this study were to report our microbi-
ological and clinical experiences with these pathogens between
2001 and 2011 and to provide data to evaluate the relative value of
each component of the recommended testing methodology.
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Population. All stool and rectal swab specimens submitted to the micro-
biology laboratory at SLCH for enteric bacterial culture between 1 January
2001 and 31 December 2011 were included in this analysis. Clinical and
laboratory data pertaining to patients with positive SMAC agar culture
and/or positive EIA results were extracted from electronic medical re-
cords. Cases of diarrhea-associated HUS were identified by reviewing all
electronic medical records from the study period for patients with a pri-
mary or secondary diagnosis of HUS (International Classification of Dis-
eases 9 [ICD-9] code 283.11). HUS was defined stringently using the cri-
teria of anemia (hematocrit level of 30%), thrombocytopenia (platelet
count of 150,000 cells/mm3), and azotemia (creatinine level above the
upper limit of the reference range for age) (2, 31, 32).
Human study approval. This study was approved by the Human Re-
search Protection Office of Washington University School of Medicine.
Laboratory methods. All stool and rectal swab samples were cul-
tured on blood agar with ampicillin, Hektoen enteric agar, Mac-
Conkey agar, SMAC agar, Campylobacter blood agar, Yersinia selective
agar, and Gram-negative (GN) broth for the detection of enteric patho-
gens (all media were from Remel, Lenexa, KS), according to standard
laboratory procedures. Cultures were inoculated upon specimen receipt
(24 h per day and 7 days per week). SMAC agar cultures were examined for
non-sorbitol-fermenting colonies, which were then tested with an E. coli
O157 latex agglutination test and autoagglutination control (Remel, Le-
nexa, KS) to presumptively identify E. coli O157. The identification of
latex-positive colonies was confirmed according to standard laboratory
procedures. Following incubation, the Premier EIA was performed on the
overnight GN broth culture for detection of Shiga toxins 1 and 2 (Merid-
ian Bioscience Inc., Cincinnati, OH). All isolates of E. coli O157, as well as
an aliquot of each positive GN broth culture (if EIA results were positive
and SMAC agar culture results were negative), were forwarded to the
Missouri State Public Health Laboratory (Jefferson City, MO) for confir-
mation by PCR and serotyping. As we had incomplete H typing reports for
many E. coli O157 isolates, we do not specify serotypes and indicate only
serogroups.
Statistical analysis. Student’s t test, Fischer’s exact test, and analysis of
variance (ANOVA) were used to evaluate the data using SPSS v20 (IBM,
Chicago, IL). Two-tailed P values of0.05 were considered significant.
RESULTS
Enteric pathogens detected. During the 11-year study period,
14,977 enteric cultures were performed with stool or rectal swab
specimens, and a bacterial pathogen was isolated in 1,238 cases
(8.3%). Pathogens detected included Shigella spp. (n 582 [3.9%
of total cultures]), Salmonella spp. (n 200 [1.3%]), Aeromonas
spp. (n 144 [1%]), Campylobacter jejuni (n 143 [1%]), E. coli
O157 (n  65 [0.4%]), Yersinia enterocolitica (n  59 [0.4%]),
non-O157 STEC (n 35 [0.2%]), Plesiomonas shigelloides (n 8
[0.05%]), and Edwardsiella tarda (n 2 [0.01%]) (Table 1).
Recovery of STEC. Of the specimens that screened positive for
STEC by one or both methods (n 107), STEC strains were iso-
lated from 100. While the majority of STEC isolates belonged to
serogroup O157 (n 65), 35 isolates, representing 12 additional
STEC serotypes, were identified by the Missouri State Laboratory
(Table 2). Among the 65 E. coli O157 isolates, 57 (88%) were
initially detected by both screening methods, two (3%) by EIA
alone, and six (9%) by SMAC agar culture alone (Table 3). All 35
non-O157 STEC isolates were initially detected by EIA alone.
STEC was isolated from samples collected in all seasons, with both
O157 STEC and non-O157 STEC infections being detected
throughout the year over the entire study period (Fig. 1).
Clinical features of STEC infections. The clinical features of
patients with O157 and non-O157 STEC infections are provided
in Table 4. The HUS rate among the 100 subjects whose stool
specimens contained an STEC strain isolated at SLCH was 16%,
including 13 (20%) of 65 patients infected with E. coli O157 and 3
(9%) of 35 patients infected with non-O157 STEC (P  0.14).
Grossly bloody stools, as established by patient history or direct
observation by a clinician, were reported for 59 (94%) of 63 sub-
jects from whom E. coli O157 was cultured, with data not being
available for two subjects. In comparison, grossly bloody stools
were reported for 19 (66%) of 29 subjects from whom non-O157
TABLE 1 Isolates recovered from all routine stool cultures from 2001 to 2011
Species isolated
No. (%) of isolates in:
Total no.
(%)2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Total 1,345 1,227 1,283 1,122 1,178 1,179 2,185 1,248 1,585 1,437 1,188 14,977
Shigella spp. 18 24 37 4 2 27 166 17 184 102 1 582 (3.9)
Salmonella spp. 26 24 17 11 17 18 25 17 12 15 18 200 (1.3)
Aeromonas spp. 14 26 16 6 7 9 19 16 12 12 7 144 (1.0)
Campylobacter jejuni 10 11 7 13 11 13 20 21 11 11 15 143 (1.0)
E. coli O157 2 3 4 6 14 8 7 6 8 0 7 65 (0.4)
Yersinia enterocolitica 12 8 6 10 5 7 2 3 3 1 2 59 (0.4)
Non-O157 STECa 1 1 3 2 3 6 3 4 5 5 2 35 (0.2)
Plesiomonas
shigelloides
0 0 2 0 2 0 1 1 1 0 1 8 (0.05)
Edwardsiella tarda 0 0 1 0 0 0 0 0 0 1 0 2 (0.01)
a STEC, Shiga toxin-producing E. coli.
TABLE 2 Serotype identification of STEC isolates from 2001 to 2011
Serotype No. of isolates
Total (serotype-confirmed STEC) 100
E. coli O157a 65
E. coli O103 9
E. coli O145 6
E. coli O111:nonmotile 6
E. coli O26 3
E. coli O121 3
E. coli O45:H2 2
All othersb 6
a Includes 60 serotype-confirmed E. coli O157:H7 isolates and 5 serogroup-confirmed
E. coli O157 isolates, not further specified.
b Includes one isolate each of the following E. coli strains: O91:nonmotile, O128:H2,
O165:nonmotile, O174:H21, O177:nonmotile, and O-rough:nonmotile.
Schindler et al.
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E. coli was cultured (P 0.001). The median age, gender distribu-
tion, presence of fever (patient or physician report), need for di-
alysis if HUS ensued, and mode of specimen collection (rectal
swab versus diaper or cup specimen) did not differ significantly
between O157 and non-O157 STEC infections, although the rate
of hospitalization was greater for patients infected with E. coli
O157 (91% versus 66%; P  0.005). Also, among hospitalized
patients, those infected with E. coli O157 had significantly longer
lengths of stay than did those infected with non-O157 STEC (me-
dian of 4 days [range, 0 to 35 days] versus 1 day [range, 0 to 12
days]; P  0.003). Patients infected with E. coli O157 did not
significantly differ from those infected with non-O157 STEC with
respect to laboratory values at presentation, including white blood
cell counts, hemoglobin levels, hematocrit values, platelet counts,
and creatinine levels.
Microbiological findings for patients with diarrheal HUS.
During the study period, 92 children had HUS as a primary or
secondary diagnosis (Fig. 2). Of these, 62 met the diagnostic cri-
teria for diarrheal HUS at the time of presentation, although only
16 (26%) of these individuals had STEC isolated from stool spec-
imens at our institution. Of the HUS cases in which STEC was
isolated either at our institution or at another hospital (n 31), 28
(90%) were attributed to E. coli O157. Among the cases in which
STEC was not isolated, Shiga toxin was detected at another hos-
pital in two cases, one in which the patient had negative culture
results at our institution and one in which cultures were not per-
formed at our institution. Non-O157 STEC was isolated from
three HUS cases. Notably, the sister of one of those patients was
hospitalized at the same time as the patient and was infected with
serotype-confirmed E. coli O157.




No. of cases detected bya:



















Total 14,977 6 0 0 2 35 6 57 0 1
2001 1,345 2 0 0 0 1 1 0 0 0
2002 1,227 0 0 0 0 1 2 3 0 0
2003 1,283 0 0 0 0 3 0 4 0 0
2004 1,122 0 0 0 0 2 0 6 0 0
2005 1,178 0 0 0 0 3 1 14 0 0
2006 1,179 1 0 0 0 6 1 7 0 0
2007 2,185 2 0 0 1 3 1 4 0 0
2008 1,248 0 0 0 0 4 0 6 0 1
2009 1,585 0 0 0 1 5 0 7 0 0
2010 1,437 0 0 0 0 5 0 0 0 0
2011 1,188 1 0 0 0 2 0 6 0 0
a EIA, enzyme immunoassay; SMAC, sorbitol-MacConkey; STEC, Shiga toxin-producing E. coli.
FIG1 Shiga toxin-producing E. coli (STEC) and hemolytic uremic syndrome (HUS) cases by month from 2001 to 2011. The numbers of cases of O157 STEC and
non-O157 STEC recovered in culture and the number of cases of HUS are shown according to the month of presentation during the 11-year study period. Cases
of HUS (established by strict diagnostic criteria) were ascertained through ICD-9 codes and chart review.
Detection of STEC in Children with HUS
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Cost analysis. We have estimated the cost of performing a
SMAC agar culture as $1 per culture, including consumable ma-
terials and technician time, totaling $14,977 over the study period.
The cost of performing a STEC EIA at our institution, including
consumable materials and technician time, is considerably higher,
estimated as $15 per test, totaling $224,655 in testing over the
11-year study period. During this period, 94 cases of STEC (in-
cluding both E. coli O157 and non-O157 STEC) were detected by
EIA, resulting in an approximate cost of $2,390 per positive result.
All except two of the E. coli O157 infections were also detected by
SMAC agar culture. The cost of EIA detection of non-O157 STEC,
which would have gone undetected if only SMAC agar cultures
had been performed, was $6,419 per positive result.
DISCUSSION
To our knowledge, this study represents the largest evaluation of
the diagnostic yield of unbiased simultaneous testing of stool sam-
ples with an agar-based method for E. coli O157 detection and an
EIA for Shiga toxin detection. Non-O157 STEC represented ap-
proximately one-third of the cases, and E. coli O157 and non-
O157 STEC were detected throughout the year. One-quarter of
the infections would have been missed if STEC screening had been
restricted to the summer months, a strategy proposed by some
groups (33). Importantly, the EIA failed to detect six cases ofE. coli
O157, the most clinically actionable serotype of STEC, emphasiz-
ing the shortcomings of using this assay as a stand-alone test (14,
17–21, 34).
Our institutional recovery rates of 0.6% for all STEC strains
and 0.4% for E. coli O157 from all stool cultures over the 11-year
study period resemble rates reported for a Boston pediatric insti-
tution from 2004 to 2009 (35) but are lower than rates reported for
Seattle Children’s Hospital (3.5% STEC and 2.0% E. coli O157)
(21). This discrepancy may be attributable to smaller numbers of
TABLE 4 Clinical features of patients with STEC isolated from stool samples, according to serotype
Parameter E. coli O157 (n 65) Non-O157 STEC (n 35) P
Age (median [range]) (yr) 7.5 (0.9–17.1) 8.6 (1.0–18.4) 0.26
Male (no. [%]) 34 (52) 21 (60) 0.46
Admitted to hospital (no./total no. [%]) 59/65 (91) 23/35 (66) 0.005
Length of hospital stay (median [range]) (days) 4.0 (0–35) 1.0 (0–12) 0.003
STEC reported prior to discharge from hospital (no./total no. [%]) 52/65 (80) 16/35 (46) 0.001
Fever by report or examination (no./total no. [%]) 17/57 (30) 3/26 (12) 0.07
Met clinical criteria for HUS (no./total no. [%]) 13/65 (20) 3/35 (9) 0.14
Received dialysis (no./total no. [%]) 8/65 (12) 1/35 (3) 0.12
Grossly bloody stool by report or examination (no./total no. [%]) 59/63 (94) 19/29 (66) 0.001
Culture submitted on rectal swab (no./total no. [%])a 8/65 (12) 9/35 (26) 0.09
White blood cell count at presentation (median [range]) (1,000 cells/mm3) (no.) 11.3 (5.0–30.0) (61) 9.1 (6.0–42.0) (28) 0.26
Hemoglobin level at presentation (median [range]) (g/dl) (no.) 13.2 (6.2–16.9) (61) 13.1 (6.9–15.9) (28) 0.65
Hematocrit at presentation (median [range]) (%) (no.) 38.0 (18.0–49.3) (61) 34.8 (19.3–44.9) (28) 0.68
Hematocrit nadir (median [range]) (%) (no.) 32.9 (13.6–45.8) (62) 33.2 (15.0–40.5) (29) 0.12
Platelet count at presentation (median [range]) (1,000 cells/mm3) (no.) 246 (18–452) (60) 239 (27–409) (28) 0.47
Platelet count nadir (median [range]) (1,000 cells/mm3) (no.) 199 (8–406) (62) 194 (14–373) (29) 0.46
Creatinine level at presentation (median [range]) (mg/dl) (no.) 0.4 (0.2–10.5) (60) 0.6 (0.2–3.7) (29) 0.97
Peak creatinine level (median [range]) (mg/dl) (no.) 0.6 (0.2–10.4) (61) 0.6 (0.2–5.0) (29) 0.16
Creatinine level outside reference range for age and gender (no./total no. [%]) 13/61 (21) 4/29 (14) 0.57
a All other cultures were stool specimens received in a cup or diaper.
92
with HUS as primary or
secondary diagnosis 
69 
met HUS criteria during
present admission/ visit 
23
did not meet HUS during
present admission/visit
12 no diarrheal illness
     10 remote history of HUS 
     2 incorrect ICD9 code 
11
 diarrheal illness 
7 no diarrheal illness 
     4 atypical HUS 




     2 E. coli O111
     1 E. coli O121
     1 no STEC recovered
3 NSF on SMAC
     3 E. coli O157
3 no culture 
     1 E. coli O157 at OSH 
     2 no STEC recovered 
42 negative cultures
     14 E. coli O157 at OSH 
     28 no STEC recovered
10 EIA positive and NSF on
SMAC
     10 E. coli O157
FIG 2 Features of patients with HUS as a primary or secondary diagnosis from 2001 to 2011. The chart diagrams the pertinent clinical and laboratory features
of all patients with an ICD-9 code of 283.11 (hemolytic uremic syndrome) for a primary or secondary diagnosis during the 11-year study period. NSF,
non-sorbitol fermenter; OSH, outside hospital; SMAC, sorbitol-MacConkey agar.
Schindler et al.
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subjects in the Seattle study (n 254) and restriction to patients in
the emergency department in Seattle and/or to regional variability
in STEC prevalence. It would be inappropriate to compare our
institutional STEC recovery rates to the STEC recovery rates re-
ported by the CDC during the same time period, given the pre-
analytic bias introduced into the CDC data by the variability of
STEC detection methods used by the reporting laboratories. Of
note, the majority of non-O157 STEC serotypes reported by the
CDC FoodNet for 2011 included O26, O103, O111, O121, O45,
and O145, which were also the most frequently isolated serotypes
in our study (36).
Our data demonstrate the severity of STEC infections inclusive
of and beyond E. coli O157, with over 80% of all patients with
STEC isolated from their stool specimens during the study period
being admitted to the hospital. Our demonstration of higher ad-
mission rates and longer lengths of stay among children infected
with E. coliO157 than among those infected with non-O157 STEC
provides additional evidence in support of the concept that E. coli
O157 causes more severe illness than does non-O157 STEC. The
finding that grossly bloody stools were reported more frequently
for subjects from whom E. coli O157 was isolated underscores the
significance of specifically asking patients and patients’ parents
about the presence of blood in the stools, as well as examining the
appearance of fresh stools in the clinical setting. While our data
emphasize the clinical significance of blood in the stools, we think
it would be unwise to task receiving laboratory technicians with
triaging STEC testing on the basis of the presence of blood in the
stools. Slutsker and colleagues assessed the utility of laboratory
evaluation for the presence of blood in stool specimens from
which E. coli O157 was isolated (37). They found that blood was
visible in 63% of specimens at the time of laboratory receipt, sug-
gesting that nearly one-half of all cases of E. coli O157 would have
been missed if screening had been restricted to specimens with
visible blood. It is not uncommon for the blood in stool specimens
to be oxidized and thus not readily visible in the samples by the
time the specimens arrive in the laboratory; for rectal swab spec-
imens or fecal specimens in transport medium, it is nearly impos-
sible to assess the absence or presence of blood in most cases.
The overall percentage of HUS cases that were culture negative
(50%) is consistent with a report from over 2 decades ago in the
Pacific Northwest (9) and from a more recent multicenter study of
children with diarrhea-associated HUS (38). Of note, the classifi-
cation of stool specimens received for culture as formed or un-
formed was not captured or reported in any of these studies, in-
cluding ours. The failure to isolate STEC from the stool may be
explained by the natural history of STEC infections. In many
cases, patients become ill with diarrhea, which variably progresses
to bloody diarrhea, followed by resolution of the enteric symp-
toms; hemolysis, thrombocytopenia, and kidney injury do not
occur until late in the disease, often after the diarrhea has resolved.
In one prospective study, the likelihood of isolating E. coli O157
was shown to be highest earlier in the course of illness, with the
pathogen being detected in 96% of HUS cases with cultures ob-
tained within 6 days after the onset of diarrhea and in 33% of stool
cultures obtained more than 7 days after the onset of diarrhea (9).
Indeed, of 42 patients with HUS who had negative stool cultures in
our laboratory, 14 had E. coliO157 isolated prior to transfer to our
institution. These findings are consistent with previously pub-
lished reports demonstrating that the ability to isolate E. coli O157
decreases if cultures are performed after HUS is diagnosed, al-
though serological evidence of recent infection with E. coli O157
has been reported for a subset of patients whose stools do not yield
STEC (13, 39–41).
The failure to detect STEC in the stool at the time of HUS
diagnosis may reflect the clearance of E. coli O157 prior to diag-
nosis. Even when non-O157 STEC is isolated from patients with
diarrhea-associated HUS, the significance of this finding is not
always clear, with multiple examples of coinfection with E. coli
O157 and non-O157 STEC (5, 13, 40, 42, 43). Although we did not
perform serological testing in this study, there was circumstantial
evidence for a dual STEC infection in one patient with HUS from
whom only STEC O111 was isolated, as that patient’s sister was
infected with E. coli O157 at the same time.
Isolated Shiga toxin EIA testing without concomitant SMAC
agar culturing has clear utility in selected situations, such as very
rare outbreaks of infections caused by non-O157 STEC (44–47).
However, Shiga toxin EIA testing is frequently used in situations
in which these circumstances do not apply, as the lone methodol-
ogy for detecting STEC, including E. coli O157 (30). Our data now
present a basis on which to measure the value of blanket screening
using an EIA. The large discrepancy between the cost of adding an
SMAC agar plate to each routine culture ($1 per culture) and the
cost of adding an EIA to each culture ($15 per culture) is a prac-
tical consideration for many laboratories that perform STEC
screening. In this study, the chief value of STEC detection by EIA
was in the identification of E. coli O157 that was not detected on
SMAC agar in two cases (a situation that has been reported previ-
ously [48]) and the identification of three cases of HUS associated
with non-O157 STEC. However, we do not wish to minimize the
value of finding a cause of illness among the 35 patients with
non-O157 STEC infections, many of whom were treated by one of
the authors (P.I.T.), even if they did not develop HUS. Most of
these patients were sufficiently ill to be hospitalized, and the iden-
tification of an etiology provided assurance that this event would
be self-limiting.
Our data also demonstrate pitfalls in evaluating the role of
non-O157 STEC in HUS solely by examining laboratory data. By
concurrently performing an analysis of all culture results from
patients meeting the diagnostic criteria for HUS, as ascertained by
reviewing all electronic medical records associated with the ICD-9
code for HUS, we were able to capture culture-negative cases.
Without taking into account culture-negative cases or examining
records for microbiology results obtained before transfer to our
institution, we might have concluded that 19% of HUS cases are
caused by non-O157 STEC. Other laboratory-based data suggest
that non-O157 STEC causes, overall, a similar number of cases of
HUS as does E. coli O157 (49) but, as this study demonstrates, the
proportion of culture-negative HUS cases is appreciable. If non-
O157 STEC is cleared more slowly than E. coli O157, then labora-
tory-based series might have an additional ascertainment bias in
favor of associating non-O157 STEC with HUS.
Early recognition of children at risk for HUS is strongly asso-
ciated with good outcomes (i.e., avoidance of anuria if HUS en-
sues) (26), and it would be worthwhile to determine why cases are
not being detected earlier. In our experience, positive culture re-
sults prompt recognition that patients are at risk for HUS, leading
providers to seek consultation and/or to provide aggressive intra-
venous volume expansion, which is associated with milder HUS
courses if this complication develops (26, 38, 50, 51). When pa-
tients are admitted with HUS, it is important to attempt to isolate
Detection of STEC in Children with HUS
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STEC, and particularly E. coli O157, from the earliest possible
specimens available. This involves identifying the source of the
original culture and confirming that the appropriate microbiolog-
ical methods were applied if testing was performed and the results
were negative.
The major strengths of the present study are the large number
of samples evaluated, which encompass more than a decade’s
worth of data, and the systematic ascertainment and review of all
cases with a diagnosis code for HUS, irrespective of culture results.
However, our study has several limitations, chiefly its retrospec-
tive format and the study site, i.e., a large, urban, tertiary care
hospital. Our observations may not be directly applicable to com-
munity hospitals or outpatient settings, which are often the first
point of contact with the medical system for children with diar-
rhea.
In conclusion, our retrospective review demonstrates that op-
timal detection of STEC is achieved by the simultaneous use of an
agar-based method to detect E. coli O157 and a test to detect Shiga
toxin. Consistent with previous studies, we have determined that a
subset of E. coli O157 infections will not be detected if an agar-
based method is excluded from the enteric culture workup; this
has both clinical and public health implications. The best practice
would be concomitant use of an agar-based method and a Shiga
toxin EIA, but a Shiga toxin EIA should not be considered to be an
adequate stand-alone test for detection of E. coli O157 in clinical
samples.
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